Latest Subcutaneous T-cell lymphoma Stories
Topical research report “OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018” drawn up by GlobalData is now available at MarketPublishers.com.
ResearchMoz.us includes new market research report "Peripheral T-Cell Lymphomas PTCL Clinical Trials Review, H1, 2014" to its huge collection of research reports.
Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North
Australian researchers say the combination of a psychiatry drug with a photosensitizer may work “synergistically” in patients with a certain kind of Non-Hodgkin’s Lymphoma. Raleigh,
NK/T-cell lymphoma is a very aggressive form of cancer, and currently has no effective treatment along with having a poor prognosis. This subtype of lymphoma is pretty rare in the United States, but is responsible for a large number of deaths in Asia, particularly China and Korea.
B cell lymphomas are a group of cancers of that originate in lymphoid tissue from B cells, the specialized immune cell type that produces antibodies.
The product, once available in the clinic, could be the first to hit a pathway that drives multiple types of lymphoma.
Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are being published today (embargoed for 4 pm) in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine.
WHITE PLAINS, N.Y., Aug.